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 Periodontal disease affects 47% of Americans over 30 and is a growing global concern.  
Current treatments for periodontal disease focus on the mechanical elimination of periodontal 
biofilms.  Very few treatments are available that target the rampant, unregulated host immune 
response that is ultimately responsible for tissue degradation.  BET proteins have been shown 
to play critical roles in inflammatory gene regulation and are therefore potentially ideal 
therapeutic targets for treating periodontal disease.  RVX-208 is a selective BET-inhibitor with a 
high affinity for Bromodomain 2 (BD2) as compared to BD1 in BET proteins.    Our previous 
studies have shown that RVX-208 inhibits inflammatory cytokine production and suppresses 
osteoclast differentiation.   Cell culture assays have provided proof of concept for RVX-208 and 
its feasibility as a treatment for periodontal disease.  As such, our long term goal is to develop 
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RVX-208 as a front-line treatment for periodontitis.  The objectives of this study were to 
determine the ability of RVX-208 to reduce bone loss in a ligature-induced periodontitis model, 
and to further investigate the mechanisms through which RVX-208 mediates its anti-
inflammatory and osteoclastogenesis-suppressive effects.  The specific aims of this study were: 
1) To further validate the in vivo effects of RVX-208 on a ligature-induced periodontitis model in 
rats, and 2) To determine the molecular mechanisms of RVX-208 on preventing alveolar bone 
loss in periodontal disease.  To investigate, a ligature-induced periodontitis model was created 
in rodents.  Those rodents were treated with increasing dosages of RVX-208 (0-2.5 mM) by 
subgingival injection every other day.  After 2 weeks, the maxillae were harvested and analyzed 
via a micro-CT protocol that had been created and validated through statistical analyses.  To 
study the ability of RVX-208 to suppress osteoclastogenesis, RAW264.7 cells were induced into 
osteoclasts by RANKL and then treated with RVX-208.  To ensure RVX-208 was not species 
specific, THP-1 cells were challenged with either E. coli-LPS or P. gingivalis bacteria and then 
treated with RVX-208.  Linear and volumetric micro-CT analysis showed that RVX-208 could 
significantly ameliorate bone loss in a ligature-induced periodontitis model.  RVX-208 was 
shown to prevent osteoclast differentiation by suppressing the expression of genes closely 
associated with osteoclast differentiation and maturation.  RVX-208 was found to not be 
species specific, as it was able to mediate its effects on a human cell line, and had consistent 
anti-inflammatory effects regardless of whole pathogen or LPS-induced inflammatory response.  
Therefore, RVX-208 is a promising therapeutic for treatment of periodontal diseases. 
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  CHAPTER 1: INTRODUCTION 
 
1.1 SCOPE OF PERIODONTAL DISEASE 
As one of the most common inflammatory diseases, periodontitis is systemic amidst global 
populations.  It currently affects approximately 50% of Americans (1) and continues to increase 
steadily in prevalence worldwide (2).  In addition to the well-documented inflammation and 
bone-loss attributed to periodontitis, periodontal disease in its more severe forms has also 
been found to increase the patient’s risk of systemic diseases such as rheumatoid arthritis, 
atherosclerosis, adverse pregnancy outcomes, pneumonia, and even cancer (3-8).  Partially due 
to its pervasiveness, periodontal disease has become a major burden on the healthcare systems 
in place around the globe, affecting 11% of the population and making it the 6th most prevalent 
health condition worldwide (9).  Characterized by microbial dysbiosis and unregulated 
inflammation, severe periodontitis will ultimately result in destruction of the periodontal tissue 
and tooth loss.  The wide range of symptoms, from swollen and/or sore gums, loose and/or 
drifting teeth, to halitosis and toothache, have a severe detrimental impact on the physical, 
social, and psychological aspects of a patient’s quality of life.   
1.2 PATHOGENESIS OF PERIODONTAL DISEASE 
While a triad of oral anaerobic bacteria, including P. gingivalis, Treponema denticola, and 
Tannerella forsythia, are traditionally considered the primary causative agents for the disease 
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itself (10), it is the host immune response to the microbiotic insults that ultimately leads to 
tissue damage (11).  The dysbiosis of commensal oral microbiota and subsequent interaction 
with the host immune response persist through bouts of activity and quiescence, until the 
affected tooth or microbial biofilm is therapeutically removed and the inflammation subsides 
(12).  Thus, the inflammatory cascade provides a vehicle through which the deleterious effects 
of periodontitis are administered.  More specifically, a chronic and robust inflammatory 
response induces a constitutive overproduction of pro-inflammatory cytokines, including tumor 
necrosis factor-alpha (TNF-a) and interleukin-6 (IL-6) (13).  This overabundance of pro-
inflammatory cytokines promotes the generation and release from the bone marrow of 
osteoclast precursors (14), which subsequently differentiate into osteoclasts, ultimately leading 
to irreversible tissue degradation and bone destruction.  Additionally, formation of a 
periodontal pocket stemming from degradation of the gingival tissue creates an opportunity for 
unfavorable microbial colonization (15), furthering the oral dysbiosis and perpetuating the 
vicious cycle of bacterial infection common in periodontal diseases. 
As the dysbiosis of periodontitis evolves, the overgrowth of microbial commensals drives 
the activation of specific pathogen recognition receptors (PRRs) including NOD1 and Toll-like 
receptors (TLRs).  In addition to activating these recognition receptors, evidence suggests that 
bacterial pathogens are also able to induce extravagant epigenetic modifications, leading to the 
activation of pro-inflammatory pathways (16).  The impact of specific epigenetic modifications, 
including DNA methylation and histone acetylation, on periodontal disease remains a topic of 
intense focus.  It is well established that the acetylation of histones relaxes the chromatin and 
leads to enhanced transcription of many of the inflammatory genes commonly upregulated in 
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periodontitis.  While the specifics remain unclear, NF-kB signaling appears to play a key role in 
connecting histone modifications to disease progression (17).  NF-kB activates the innate 
immune response and protects against infections (18).  However, chronic NF-kB activation and 
overexpression cause the osteoclast differentiation and bone resorption characteristic of 
periodontitis pathogenesis (19).  Thus, it is the disruption of equilibrium between the innate 
immune response and chronic activation of the NF-kB pathway that ultimately leads to overall 
tissue degradation in periodontal disease even after the pathogens have been removed.  
Martins et. al explored the ability of the bacteria known to cause periodontitis, P. gingivalis, to 
affect the NF-kB pathway through epigenetic modifications and found that the modifications 
were induced primarily through acetylation of histones and downregulation of DNA 
methyltransferase 1 (DNMT1) (17).  Additionally, PRRs were found to induce histone 
modifications as well (17).  These findings suggest that disruption of dysbiosis-mediated 
epithelial injury may inhibit PRRs and that targeting the disruption of histone acetylation may 
provide the foundation for treating epigenetically-relapsing periodontitis (17). 
1.3 CURRENT TREATMENT STRATEGIES FOR PERIODONTAL DISEASE 
Current treatment strategies for periodontitis focus on the eradication of oral pathogens at 
the site of infection through mechanical means, usually by surface debridement procedures 
with or without adjunctive therapies, including the use of antiseptics and/or antibiotics (20).  
While it is thought that the removal of subgingival plaque and elimination of the biofilm is 
sufficient to reduce the inflammatory response and remediate tissue destruction, recent meta-
analyses suggest otherwise.  Studies show that after initial mechanical debridement, the 
microbial load drops to 0.1% (21).  However, the bacteria is able to recolonize within a week 
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with less pathogenic composition (22), potentially leading to re-infection.  Moreover, surface 
debridement does not account for the host immune response that is ultimately responsible for 
the inflammation, suggesting that mechanical means alone are insufficient despite remaining 
the treatment of choice for periodontal disease (23).  In conjunction with mechanical methods 
of treatment, chlorhexidine is among the most common antiseptic treatments because of its 
broad-spectrum antimicrobial activity (24).  Yet despite its efficacy and ease of use, many 
limitations have been reported, including tooth discoloration, oral mucosal erosion, parotid 
swelling, and bitter taste, all ultimately contributing to patient non-compliance (25).  
Alternatively, several classes of antibiotics have been suggested for the treatment of 
periodontal infections, including tetracyclines, macrolides, β-lactams, and nitroimidazoles (26, 
27).  Because systemically administered antibiotics can penetrate deep into periodontal tissue, 
they are able to reach oral pathogens that are not otherwise accessible via mechanical means 
or locally applied antibiotics (28).  However, this treatment method requires a high patient 
compliance, has been associated with undesirable side effects, and can facilitate antibiotic 
resistance (29, 30).  Additionally, concerns about the efficacy of the aforementioned 
antimicrobials in treatment of periodontitis have been raised within the last few years.  
Yamaguchi et. al. found that P. gingivalis cells residing in biofilms are less susceptible to 
antimicrobials such as chlorhexidine when compared with planktonic cells (31).  More 
specifically, and perhaps more worrisome, biofilms can be up to 500 times less sensitive to 
antibiotics (32).  Furthermore, several studies have examined the antibiotic susceptibility of 
subgingival microflora isolated from patients suffering from periodontitis and found that 74.2% 
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of patients harbor pathogens resistant to at least one standard antibiotic (29), further validating 
concerns of an overall increase of antibiotic resistance. 
1.4 BROMODOMAINS AS THERAPEUTIC TARGETS 
When examining the epigenetic mechanisms through which inflammatory genes are 
expressed, it becomes clear that the post-translational modifications (PTMs) of histones are 
some of the most important determinants of chromatin structure and function.  Among the 
many PTMs, histone acetylation (Fig. 1) is generally associated with enhanced DNA accessibility 
and transcriptional activation (33).  Acetylation weakens the bond between histone and DNA by 
removing the positive charge on lysine residues and by introducing slight structural changes 
within the histone itself.  As a result, the nucleosome loosens, and the DNA becomes more 
readily accessible.  In addition to increasing DNA accessibility, acetylation of the histone also 
recruits transcription and chromatin-remodeling factors that lead to enhanced transcriptional 
activity (34).  These factors are traditionally recruited via a bromodomain (BRD), an epigenetic 
reader domain that specifically recognizes ε–N-acetylated lysine residues (Kac) (35).  In humans, 
there are at least forty proteins that interact specifically with the bromodomain (36), including 
histone acetylases (HATs), helicases, scaffolding proteins and other co-factors that control gene 
transcription, among the most important of which is positive transcription elongation factor b 
(PTEFb).  By inhibiting the BRD’s interaction with these bromodomain proteins, the DNA would 
remain in a dormant state and the proteins for which that genomic sequence codes would be 
suppressed.  Without BRDs, gene transcription is slowed or halted altogether.  As such, the 
discovery of high-affinity small molecule BRD inhibitors has introduced new avenues through 
which to treat epigenetic symptoms in a wide range of diseases. 
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Figure 1: Histone acetylation and deacetylation regulated by HAT and HDAC enzymes alters chromatin structure.  
Acetylation of histones increases the accessibility of chromatin and allows DNA binding proteins to interact with 
exposed sites to activate the genes.  
1.4.1 BET PROTEINS 
The bromodomain and extra-terminal (BET) family is a distinct group of bromodomain 
proteins that includes BRD2, BRD3, BRD4, and BRDT, each of which are ubiquitously expressed 
in mammalian tissue except for BRDT, which is testis specific (37).  Each BET isoform contains 
two consecutive bromodomains (Fig. 2) (BD1 and BD2) which share highly similar structures but 
differ in their functions regarding gene transcription (38-41).  While the roles of BRD2 and BRD4 
in cell cycle control (42) and transcription elongation (41) have been well established, their 
function in inflammatory responses in vivo remains poorly explored. 
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Figure 2: Motif alignment of double bromodomain-containing BETs.  The dual tandem BDs are always positioned 
at the amino terminus.  The recruitment of transcription factors takes place either through ET domains or 
through SEED domains rich in Ser, Glu, and Asp. 
1.4.2 THE ROLE OF BET PROTEINS IN THE INFLAMMATORY RESPONSE 
BRD4 has recently emerged as a key transcription regulator of NF-kB-dependent 
inflammatory gene expression due in part to its ability to activate CDK9 of P-TEFb (Fig. 3), 
ultimately facilitating the RNAPII-dependent transcription elongation (42-44).  NF-kB is an 
inducible transcription factor that is widely considered to be the master regulator of innate and 
immune responses.  NF-kB is a heterodimer composed of ReIA and p50 and remains 
sequestered in the cytoplasm by its association with IkBα (45).  Acetylation of the ReIA subunit 
at lysine-310 regulates the transcriptional activation of NF-kB target genes (46).  When 
stimulated, IkBα is phosphorylated and degraded, facilitating the nuclear translocation of NF-kB 
and the activation of NF-kB target genes (45, 47) (Fig. 4).  Importantly, one of NF-kB’s target 
genes is its inhibitor, IkBα, creating a negative-feedback regulation that prevents sustained NF-
kB activation and prolonged inflammatory response (45).  In addition to this negative feedback 
loop, the NF-kB pathway is subjected to many intricate layers of regulation, including various 
epigenetic modifications.  The eukaryotic translation initiation factor eIF4E has been shown to 
10 
 
be the node of the translational control of immune response via the mTOR signaling pathway or 
the MAPK-Mnk1-Mnk2-eIF4E pathway (48).  Bao et. al showed that in response to LPS 
stimulation, deletion of BRD4 in macrophages led to the sustained expression of Mknk2 and the 
enhanced activation if eIF4E, which stimulates the translation of IkBα mRNA, resulting in 
decreased NF-kB-dependent inflammatory gene expression and compromised innate immune 
response (49).   Additionally, BRD4 has been shown to bind to acetylated lysine-310, suggesting 
that BRD4 helps to maintain constitutively active NF-kB by binding to acetylated ReIA (43, 46).  
These findings provide clear evidence that BRD4 has an essential role in the innate immune 
response and justify the protein as a reasonable target to influence the NF-kB inflammatory 
response.  Furthermore, a recent genetic disruption model in mice suggested that BET protein 
function is required for inflammatory cytokine gene expression (37), prompting further study of 
their relevance in the host response while leaving the exact mechanisms an enigma.  Because 
the deleterious effects of periodontitis stem from the host-response inflammatory cascade, 
elucidating the roles of the other BETs in inflammation may prove beneficial to mitigating the 
symptoms of the disease.  Namely, BET bromodomain inhibition has been shown to suppress 
LPS-induced expression of pro-inflammatory cytokines in murine bone marrow-derived 
macrophages (37). 
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Figure 3: The binding of BRD4 to acetylated histones recruits and activates cyclin-dependent kinase 9 (CDK9) of 
the positive elongation factor b complex (P-TEFb) to phosphorylate RNA polymerase II (Pol II), leading to 
increased transcription of inflammatory cytokines. 
Figure 4: The stimulation of Toll-like receptor 4 by LPS leads to the degradation of Iκ-B and NF-κB.  BRD4 then 
binds to acetylated Lysine-310 on the ReiA subunit via its two BDs and recruits p-TEFb, phosphorylating RNA 
Polymerase II and promoting the transcriptional activation of a subset of NF-κB target genes, including 
inflammatory cytokines. 
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1.5 SUPPRESSION OF INFLAMMATION BY BET-PROTEIN INHIBITORS  
 In the past decade, several small molecules have been developed to block the 
interactions between the BRDs of BET proteins and acetylated lysine residues in histones (Fig. 
5).  So far, many small molecule inhibitors targeting the BET family are being developed for 
clinical use, with most being non-selective inhibitors that display equivalent activity in both 
bromodomains BD1 and BD2.  In 2010, Nicodeme et al. successfully synthesized a compound 
(IBET762) that mimicked acetylated histones and disrupted chromatin complexes responsible 
for the expression of key inflammatory genes in activated macrophages, while also conferring 
protection against LPS-induced endotoxic shock and bacteria-induced sepsis (50, 51).  Almost 
simultaneously, Filippakopoulos et al. described a cell-permeable small molecule (JQ1) that 
binds competitively to bromodomains and displaces the BRD4 fusion oncoprotein from 
chromatin (52).  Both of these landmark findings established proof-of-concept for targeting 
protein-protein interactions of epigenetic “readers,” and ushered in a new era of epigenetic 
drug discovery.  Like all BET-inhibitors, JQ1 and IBET762 interact with the BRD pocket in a 
manner competitive with acetylated peptide binding, resulting in the displacement of BET 
proteins from acetylated chromatin in cells exposed to these inhibitors (34).  Systemic 
treatment of JQ1 prevented bone loss in inflammatory arthritis (53) and estrogen-related 
osteoporosis (53, 54).  For periodontal disease in particular, intraperitoneal injection of JQ1 in a 
murine periodontitis model inhibited inflammatory cytokine expression and prevented 
periodontal alveolar bone loss (55).  Mechanistically, JQ1 inhibits TLR2/4 expression and NF-kB 
phosphorylation and nuclear translocation in macrophages and suppresses the gene expression 
of the master osteoclast regulator NFATC1.  While JQ1 displays a high affinity for BRD4, it also 
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demonstrates an affinity for other BRDs, opening the door for potential undesirable off-target 
effects.  On the other hand, IBET762 displayed very similar selectivity profiles and binding 
affinities to JQ1, but also demonstrated the added bonus of suppressing several important 
inflammatory genes in vivo (50). Taken together, the discovery and characterization of JQ1 
established the plausibility of optimizing small-molecule inhibitors of epigenetic targets, leading 
to advances in the treatment of cardiovascular disease, obesity-associated type 2 diabetes, and 
cancer (56-61).   
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Table 1: Summaries of the current BET-inhibitors in the treatment of inflammatory diseases 
Abbreviations: GSK, GlaxoSmithKline; SGC, Structural Genomics Consortium, AS, ankylosing spondylitis; PSA, psoriasis and psoriatic arthritis
Inhibitor Target Potency Scaffold in-vitro Results in-vivo Results Affiliation Reference 
JQ1 BET 
KD = 50-190 
nM (BRD2-4, 
BRDT) 
Triazolodiazepine 
Inhibits IL-6, IL-8, and TNFa 
cytokine secretion and expression 
of matrix metalloproteinases  
Reduced synovial inflammation and joint destruction in mice 
with collage-induced arthritis, and has shown promising results 
in a mouse model of psoriasis. 
Dana-Farber 
Cancer Institute 
Filippakopoulos 
et al. (41) 
I-BET151 BET KD = 20-100 nM (BRD2-4) Dimethylisoxadole 
Suppresses expression of key LPS-
inducible cytokines and 
chemokines, including IL-6 and IL-8.  
Prevents or attenuates death in mice induced with endotoxic 
shock, and protected mice against death by sepsis. GSK 
Mirguet et al. 
(48)  
I-BET762 BET KD = 50-61 nM (BRD2-4) Triazolodiazepine 
Suppresses expression of IL1B and 
IL-6, as well as chemokines CXCL9 
and CCL12. 
Suppressed inflammation in a mouse model of severe sepsis, 
which prevented or delayed death from endotoxic shock.  Mice 
showed reduced serum levels of pro-inflammatory cytokines. 
GSK Nicodeme et al. (39) 
CBP30 CBP/p300 
KD = 26 nM 
(CBP) Dimethylisoxadole 
Inhibits IL-17A production in 
primary human cells and Th17 
responses from patients with AS 
and PSA. 
N/A SGC Hay et al. (94, 95) 
CPI-203 BET IC50 = 37 nM (BRD4) Triazolodiazepine 
Suppresses Th17 cell responses in 
explanted CF tissue and inhibited 
IL-17-driven chemokine production 
in HBEC. 
Decreased inflammation in an acute lung infection mouse 
model. N/A 
Chen et al. (96, 
97) 
PFI-1 BET IC50 = 220 nM (BRD4(1)) 
Dihydroquinazolin-
one 
Inhibits release of IL-6 and IL-8, but 
despite its tight interaction with 
BRD4, it displays a weak reduction 
in pro-inflammatory cytokines. 
N/A Pfizer Fish et al. (98) 
RVX-208 
BET 
(2nd 
BRD) 
KD = 140 nM 
(BRD4(2)) Quinazolone 
Stimulates ApoA1 transcription 
leading to a dose-dependant 
increase in ApoA1 levels. 
In African green monkeys, daily treatment increased serum 
ApoA1 and HDL-C levels.  Showed usefulness in treating a 
mouse model of atherosclerosis and hypercholesterolemia, 
inhibited production of proinflammatory cytokines, and 
reduced the formation of aortic lesions. 
Resverlogix Bailey et al. (71) 
RVX-297 BET 
IC50 = 20-80 
nM (BRD2-
4(1)) 
Quinazolone 
Suppresses pro-inflammatory gene 
expression, including IL-6, IL-1B, 
and TNFa. 
Reduced both cytokine production and gene expression in 
endotoxemic mice.  Additionally, countered disease pathology 
in rodent models of polyarthritis and prevented disease 
progression of a murine model of human multiple sclerosis.  
Zenith Epigenetics Kharenko et al. (99, 77) 
MS-402 BET KD = 77 nM (BRD4 (1)) Cyclopentanone Inhibits Th-17 cell differentiation. Ameliorates adaptive T-cell transfer-induced colitis in mice. N/A 
Cheung et al. 
(67) 
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 Among the many pan-BET inhibitors that demonstrate therapeutic potential, I-BET151 
was found to be one of the more potent and selective.  I-BET151 preferentially inhibits BRD4 (Kd 
= 50 nM), and has also been suggested as having a role in the control of the inflammatory 
response (62).  Because BRD4 associates with acetylated NF-kB (37, 63), it was theorized that I-
BET151 could selectively modulate the expression of pro-inflammatory genes associated with 
the NF-kB cascade.  Interestingly, I-BET151 was found to preferentially reduce IL-6 production 
induced by LPS in RAW267.4 cells, while having no effect on the activation of NF-kB (albeit at 
low concentrations).  Furthermore, it was found that I-BET151 does not affect TNFα, IL-1β, or 
IL-10, suggesting that bromodomain proteins inhibited by I-BET151 are selectively involved in 
the control of the production of IL-6 (62).  Similarly to JQ1, systemic treatment of I-BET151 also 
prevented bone loss in inflammatory arthritis (53) and estrogen-related osteoporosis (53, 54).  
I-BET151 also showed promise in the treatment of multiple sclerosis, as administration of I-
BET151 in the mouse experimental autoimmune encephalomyelitis (EAE) delayed onset of the 
disease and was well tolerated over a prolonged treatment period of nearly 40 days (62).  
However, the dosage of I-BET151 was unable to prevent progression of the disease, suggesting 
that other pathogenic mechanisms in the experimental model of multiple sclerosis were not 
affected by I-BET151, and highlighting the need for further study on the protein-protein 
interactions of BRD4 and I-BET151. 
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Figure 5: Bromodomain (BRD) inhibitors.  Chemical structures of representative BRD inhibitors, arranged by 
chemical class or scaffold.  In parentheses are reported the target BRDs (adapted from (34)).
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1.5.1 PROBLEMS WITH PAN-BET INHIBITORS  
 While early clinical use of the aforementioned pan-BET inhibitors has shown some 
efficacy for treatment of hematological cancers and solid tumors (64-68), the significant 
toxicities of these compounds limit most clinical translations.  For example, mice treated with 
JQ1 at efficacious exposures demonstrated dose-dependent decreases in both B- and T- 
lymphocytes with a concomitant decrease in peripheral white blood cells (69).  At higher doses, 
JQ1 caused significant body weight loss that forced the researchers to euthanize their subjects 
early (69).  JQ1 is also responsible for significant and unsatisfactory side-effects, including a 
reactivation of HIV in patients with latent infections (70), uncontrollable increases in blood 
insulin (71), and temporary male infertility due to inhibition of the testis-specific variant BRDT 
(72).  Young mice treated with the brain-permeable pan-BET inhibitor I-BET858 showed 
pharmacological suppression of BET proteins resulting in neuronal gene suppression followed 
by an autism-like syndrome (73).  Another pan-BET inhibitor currently in Phase I clinical trials 
for the treatment of hematological malignancies, OTX015, displayed a wide array of undesirable 
side-effects including thrombocytopenia, diarrhea, fatigue, nausea, dysgeusia, and 
hyperglycemia (74).  Given the far-reaching effects of BET proteins on gene transcription, the 
severe systemic toxicity observed in these cases is not surprising given the rampant and 
unselective blocking of BET-protein function by pan-BET inhibitors.  Thus, the need for BET 
inhibitors that can selectively target individual BET proteins is imperative for a safe and 
efficacious transition of these inhibitors into the clinic. 
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1.5.2 THE CASE FOR SELECTIVE BET-INHIBITORS 
 In order to minimize the known side effects of BET protein inhibition, clinical use of BET 
proteins must be geared toward inhibitors that are selective among specific BET family 
members and coupled with tissue-specific drug targeting (75).  In order to accomplish this, 
researchers focused on elucidating the distinctive functions of the two bromodomains (BD1 and 
BD2) in BET proteins, which facilitate their interactions with different lysine-acetylated histones 
and/or transcriptional proteins.  Most efforts to develop selective inhibitors have been focused 
on BRD4 due to the discovery of a gene rearrangement that links BRD4 to aggressive carcinoma 
(76).  The first bromodomain (BD1) of BRD4 anchors the molecule and its associated proteins to 
the target gene promoter and enhancer sites in chromatin through binding to histone proteins, 
while the second bromodomain (BD2) is involved in the recruitment of non-histone proteins 
(such as the pTEFb complex) to target genes (40).  Conversely, in BRD3, it is the BD1 that binds 
the non-histone protein hematopoietic transcription factor GATA1 (77).  In oligodendrocytes, 
only the inhibition of BD1 function promoted differentiation, while the reverse process was 
observed when the function of just BD2 or both BDs were blocked (39).  Similarly, the blocking 
of only BD1 by the small molecule MS-402 selectively suppressed Th17 cell differentiation while 
leaving CD4+ cells unaffected (78).  These findings all suggest that BD1 and BD2 have distinctive 
roles, despite their highly-conserved structures.   
 In addition to establishing the distinct functions of the two BDs, several studies have 
explored the roles of individual BET protein family members in regards to the regulation of 
cytokine gene transcription.  In primary epithelial cells, a knockdown of BRD2 with siBRD2 had 
no effect on the secretion of IL-6, an effect that would otherwise have been masked by a pan-
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BET inhibitor (79).  Further substantiating this role for BRD2, a knockdown of BRD2 inhibited 
LPS-induced secretion of pro-inflammatory cytokines from mouse bone marrow-derived 
macrophages (75).  While BRD4 is still present, BRD2 is the only BET protein that becomes 
enriched at the TNF-α promoter upon LPS stimulation (37).  Finally, a substantial cache of 
evidence (37, 72, 80) has been established in recent years that reinforces the definitive role 
BRD2 plays in regulating the responses of immune cells crucial to the inflammatory cascade.  In 
light of the ubiquitous nature and diverse functions of BET proteins, these observations suggest 
that establishing the exclusive effects of individual BET proteins on the regulation of cytokine 
networks is imperative to advancing treatment options.  Based on the evidence, selective BRD2 
inhibitors, designed in the context of anti-cancer treatments, would be advantageous to 
alleviating inflammatory diseases.  Furthermore, the ability to discriminate between BD1 and 
BD2 pharmacologically presents an opportunity to achieve more selective transcriptional 
effects, potentially reducing the disastrous side effects of the known pan-BET inhibitors. 
1.6 RVX-208 AS A SELECTIVE BET-INHIBITOR 
 RVX-208, a derivative of the plant polyphenol resveratrol and belonging to the 
quinazoline family (Table 1.), was first identified in 2010 as a pharmaceutical candidate for 
cardiovascular disease due to its ability to increase apolipoprotein A-I (ApoA-1) gene expression 
(81, 82).  Pharmacokinetics and oral bioavailability studied in a number of species indicated 
good oral absorption.  Additionally, RVX-208 has demonstrated a low systemic clearance rate (5 
mL/min/kg), a moderate volume of distribution (0.81/kg) at steady state, a relatively short half-
life (1.5 hours) and an oral bioavailability of 44% in cynomolgus monkeys (83).  In recently 
concluded Phase 2b trials, RVX-208 significantly increased apoA-I levels, HDL-C levels, large HDL 
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particle levels, and decreased levels of high-sensitivity C-reactive proteins (hsCRP), all in a dose-
dependent manner (84).  Moreover, a post-hoc analysis demonstrated a 55% risk reduction in 
the major adverse cardiac events (MACE) in patients receiving RVX-208, which was even more 
pronounced in patients with diabetes (up to 77%) (85). In another phase II study, short 
durations of RVX-208 treatment were shown to reduce overall glucose absorption and 
endogenous glucose production (85).  In addition to its beneficial effects on blood lipid profile, 
the MACE-reducing actions of RVX-208 are largely due to its novel anti-inflammatory actions, 
suggesting a role in the anti-inflammatory cascade.  To verify this, Jahagirdar et al. 
demonstrated a significant reduction in circulating adhesion molecules and pro-inflammatory 
cytokine interferon gamma inducible protein 10 (IP-10) when apo-E deficient mice were orally 
treated with RVX-208 in conjunction with a low-fat diet for 14 weeks (86), while simultaneously 
decreasing the level of C-C motif chemokine ligand-18 (CCL18) and interleukin-18 (IL-18).  These 
results show that the anti-atherogenic activity of RVX-208 occurs via a combination of lipid-
profile changes and anti-inflammatory activities.  A phase III clinical trial that will examine the 
effect of RVX-208 on MACE in high-risk coronary artery disease patients and further elucidate 
its cardioprotective mechanisms is currently underway and recruiting patients.   
1.7 THE SELECTIVITY OF RVX-208 
 Recently, it was found that RVX-208 preferentially binds to BD2 of BRD2 and BRD3 
proteins (86), making it a more selective BET inhibitor than the previously detailed pan-BET 
inhibitors.  RVX-208 competitively binds to the BET bromodomains and causes dissociation of 
the BET proteins from the chromatin, resulting in altered transcription.  This variability in 
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transcription results in an elevation of apoA-I and HDL, along with a suppression of 
inflammatory pathways, especially apparent in decreased levels of IL-6 (86).   
In the early years of RVX-208, the selectivity for BD2 remained poorly explored, and the 
molecular basis of the selective inhibition for BD2 over BD1 was enigmatic.  Because the active 
pockets of BD1 and BD2 are so highly conserved (their sequence similarity approaches 95%), 
developing selective inhibitors remains a significant challenge.  In mid-2017, with the help of 
extensive classical molecular dynamics simulations and hybrid density function 
theory/molecular mechanics (DFT/MM) simulations, Cheng et al. revealed that the selective 
inhibitory effect towards BD2 is achieved by the distinctive structural dynamics of the ZA-loop 
(“in/out” conformations) in BD1 and BD2, which originate from the existence of residue Asp144 
in BD1 which is replaced by His433 in BD2 (87).  This small alteration in amino acid residues 
confers a more stable inherent H-bond, accounting for the high inhibitory activity of RVX-208 in 
BD2 (87).  Furthermore, additional molecular dynamics simulations have shown that Val435 and 
His433 are the distinguishing residues of BD2 from BD1, with Leu383 and Asn429 being the 
most key residues for BD2 binding to RVX-208 (88).  With one step closer to fully understanding 
the differences between the two domains and the selectivity mechanism for preferential 
inhibition of BRD2-BD2, the development of clinically translatable BET-inhibitors seems close at 
hand.    
When examined collectively, the anti-inflammatory effects of RVX-208 denote a high 
therapeutic potential for the treatment of periodontal disease.  Its ability to suppress the host 
immune response in conjunction with its excellent safety profile observed in the completed and 
ongoing clinical trials suggest next steps are ready to be made in the development of RVX-208 
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as a treatment option.  In order to do so, the mechanisms of action of RVX-208 need to be 
better understood to avoid any undesirable off-target effects.  Additionally, in vivo studies are 
still needed to verify the effects seen in vitro. 
1.8 SUMMARY 
 Periodontitis is caused by a disruption in the oral microbial biome in conjunction with 
severe inflammation, often resulting in degradation of periodontal tissue.  The high prevalence 
of periodontitis, debilitating impacts on the quality of life of patients, limitation of current 
therapies, and the omnipresent global threat of antimicrobial resistance coupled with the 
current data concerning biofilm-mediated resistance in dental practice (89), all underscore the 
importance of implementing innovative treatment interventions to address the disease.  
Efficacious, safe, and economically-viable therapies to control the host immune response are an 
unmet need for current periodontal disease treatment.  Mechanical debridement does nothing 
to address the hyper-inflammatory state of the periodontal tissue while leaving much to be 
desired in terms of preventing re-infection, and a widespread use of broad-spectrum antibiotics 
may lead to drug resistance issues in the near future.  Subsequently, epigenetic modifiers have 
emerged as promising therapeutic targets for several inflammatory diseases, including cancer.  
Because the disease pathogenesis is dictated by the host immune response, targeting the 
overly exuberant inflammatory response is critical for controlling periodontal disease, especially 
in susceptible individuals who exhibit severe periodontal inflammation but often minimal 
plaque accumulation.  Amelioration of tissue inflammation not only halts the tissue 
degradation, but also facilitates the restoration of bacterial homeostasis in periodontal pockets 
(90).  Thus, a need arises for host-response modulation therapies.   Because of RVX-208’s 
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success in clinical trials, favorable safety profile, and documented effects on both reducing the 
inflammatory response and suppressing osteoclast differentiation, we believe there exists a 
potential therapeutic application of the drug in the treatment of periodontal disease. 
  
24 
 
CHAPTER 2: SPECIFIC AIMS 
 
 
Excessive periodontal inflammation results in the degradation of gingival tissue and 
surrounding bone, which ultimately results in tooth loss.  Many small molecule BET-inhibitors 
have been developed that either directly or indirectly target the host immune response 
ultimately responsible for periodontal disease progression, but very few show as much promise 
as RVX-208.  The overall objective of this study is to elucidate the therapeutic potentials of RVX-
208 as treatment for periodontal disease, specifically examining the molecule’s ability to reduce 
bone loss and inflammation.  The main hypothesis was that RVX-208 could inhibit alveolar bone 
loss in a ligature-induced experimental model of periodontitis by inhibiting the host 
inflammatory response and by suppressing osteoclast formation.   
2.1 Specific Aims 
The following aims were developed to test our main hypothesis: 
 Specific Aim 1: To further validate the in vivo effects of RVX-208 on a ligature-induced 
periodontitis model in rats.   
  Sub-aim 1: To validate the micro-CT protocol for analyzing linear and volumetric 
data from the periodontitis model in rats.  In order to quantitatively analyze any specimens 
from the experimental model, a standardized and validated protocol was needed that ensured 
reliable results.   
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  Sub-aim 2: To determine the effects of RVX-208 on alveolar bone loss in an 
animal periodontitis model.  The hypothesis of this experiment was that RVX-208 would reduce 
bone loss in the periodontitis model in a dose-dependent manner.  The maxillae of experiment 
subjects were harvested, and subsequently analyzed via the aforementioned micro-CT protocol.  
Both linear and volumetric bone measurements were taken.  
  Sub-aim 3: To perform a histological analysis of samples from the animal 
periodontitis model.  The hypothesis of this experiment was that the presence of inflammatory 
cell infiltrate and osteoclast activity would be significantly reduced in tissue treated with RVX-
208.  Samples from the harvested maxillae were demineralized and placed on slides.  The slides 
were then stained with H&E to investigate the morphology and to qualitatively show the extent 
of the inflammatory response.  
 Specific Aim 2: To determine the molecular mechanisms of RVX-208 on preventing 
alveolar bone loss in periodontal disease. 
  Sub-aim 1:  To determine the extent to which RVX-208 inhibits osteoclast gene 
expression.  The hypothesis of this experiment was that RVX-208 would significantly suppress 
the expression of the major genes associated with osteoclast differentiation and maturation.  
RAW264.7 cells were induced to osteoclasts via treatment with RANKL, then treated with RVX-
208 for 24 hours. RT-PCR was performed on the harvested RNA. 
  Sub-aim 2: To determine the extent to which RVX-208 suppresses the 
inflammatory cytokine production when challenged by P. gingivalis bacteria.  The hypothesis of 
this experiment was that RVX-208 would significantly suppress inflammatory cytokine 
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production in RAW264.7.  Recent findings suggest that P. gingivalis bacteria elicits a specific 
response different than that of P. gingivalis-LPS alone.  RAW264.7 were challenged with P. 
gingivalis bacteria and treated with RVX-208 for 24 hours.  
  Sub-aim 3: To determine through which bromodomain protein of the BET-
protein family the effects of RVX-208 are mediated. 
 The hypothesis of this study is that RVX-208 mediates its anti-inflammatory effects by 
primarily inhibiting the actions of BRD2.  Initially, we needed to determine that the effects of 
RVX-208 were not species specific, as our cell-culture assays almost exclusively utilized a murine 
cell model.  In order to be clinically applicable, we need to show that RVX-208 is equally as 
effective in human cells.  Secondly, once a viable human cell line is determined, a human with a 
knockdown of the BRD2 protein would provide insight as to whether or not the effects of RVX-
208 can still be seen without the presence of BRD2.   
2.1 SIGNIFICANCE OF THE STUDY 
 The purpose of these studies is to provide insight into the effects of RVX-208 on 
inflammatory diseases outside the realm of CVD, while also furthering the development of the 
molecule as a therapeutic drug for the treatment of periodontal disease.  Because the current 
therapies available for the treatment of periodontitis focus on the removal of bacterial 
pathogens, they do little to address the host immune response and often leave the periodontal 
tissue in a hyper-inflammatory state.  Thus, efficacious, safe, and economical therapies to 
directly control the inflammatory response are an unmet need for current periodontal disease 
treatment.  Recently, epigenetic modifiers have emerged as promising therapeutic targets for 
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several inflammatory diseases.  In our preliminary studies, we found that one such epigenetic 
modifier currently in phase III clinical trials, RVX-208, is a potent inhibitor for the inflammatory 
response induced by the keystone pathogen of periodontitis, P. gingivalis.  Because it not only 
suppresses inflammatory cytokine production but also inhibits osteoclast differentiation, RVX-
208’s regulation of both upstream and downstream events that lead to periodontal tissue 
destruction paves the way for a new class of therapeutics for periodontal diseases.  To further 
our understanding of RVX-208, the safety and efficacy of RVX-208 was tested via a rodent 
experimental periodontitis model in conjunction with cell culture assays and histological 
analysis.  Additionally, we examined the mechanisms of action of RVX-208 through the 
generation of a BET-protein knockout cell line by CRISPR/Cas9.  In the long run, our study may 
lead to an innovative solution to target the host immune response in periodontal patients, with 
the potential to improve the life quality of millions of periodontitis patients and reduce the 
economic burdens associated with the disease. 
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CHAPTER 3: METHODS 
 
 
3.1  SPECIFIC AIM 1: TO FURTHER VALIDATE THE IN VIVO EFFECTS OF RVX-208 ON A 
LIGATURE-INDUCED PERIODONTITIS MODEL IN RATS 
 Studies in Aim 1 seek to expand on data our lab obtained throughout a ligature-induced 
periodontitis model study in rats by developing and standardizing the protocol for quantitative 
micro-CT analyses and performing histological assessments of our samples.  With our ultimate 
goal being the clinical application of RVX-208 in the treatment of periodontal diseases, and 
having established reliable proof-of-concept results in cell culture assays, the next step in 
progression towards that goal relies on in vivo studies.  Not only were dosage ranges narrowed 
and refined, but we also standardized the quantification of our data assessment and reinforced 
our preliminary in vitro findings.  The hypothesis is that RVX-208 will significantly ameliorate 
bone loss in an experimental model of periodontitis.   
3.1.1 AIM 1.1:  TO VALIDATE THE MICROCT PROTOCOL FOR ANALYZING LINEAR-AND 
VOLUMETRIC MEAUREMENTS IN THE PERIODONTITIS MODEL IN RATS 
A reproducible and standardized micro-CT protocol is critical for the purposes of our 
research.  We wanted to examine both linear and volumetric bone data, and establish a 
standardized and reliable protocol that produced repeatable results.  The samples examined 
were maxillae harvested from the rat subjects from a ligature-induced periodontitis model that 
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were first placed in 10% formalin for 2 days, then transferred to 70% ethanol for preservation 
before and after scanning.  A maxilla sample was initially scanned using a micro-CT machine 
(Bruker SkyScan 1173 High Energy Micro-CT).  An image was reconstructed using NRecon 
Reconstruction software (Bruker) which was then opened in DATAVIEWER (Bruker) in order to 
visualize the three separate planes of the sample.  The planes were then standardized to ensure 
that every sample would have identical alignment when performing subsequent analysis.  For 
linear measurements, the standardized sagittal plane was isolated.  The cementoenamel 
junction (CEJ) midpoint between maxillary molars M1 and M2 was located using line tools 
within the software.  From that midpoint, a perpendicular line was drawn to the alveolar bone 
crest (ABC), and the measurement of that line represented your linear bone loss measurement.   
For volumetric measurements, a region of interest (ROI) was established in the 
standardized transverse plane.  The top boundary was just above the roof of furcation (ROF), 
the bottom boundary included all roots of M2, the right boundary was just outside the most 
distal roots of M1, and the left boundary was just outside the most mesial roots of M3.  That 
ROI was then saved and uploaded to CTAn Visualization software (Bruker).  In order to keep the 
measurements standardized, we found that the bone volume results were most reproducible 
when the volume of interest (VOI) included approximately 1 mm below the ROF.  The VOI 
boundaries were set with the top of the selection as the ROF and the bottom of the selection 
80 layers or 1 mm below the ROF, depending on initial scan settings.  A detailed ROI was then 
drawn by hand beginning with the lowest layer, so that the midpoints of the roots represent 
the connecting boundaries of your ROI.  The process of drawing the ROI was repeated 
approximately every 5 layers.  The frequency at which the ROI was redrawn will vary; the 
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deeper roots will not have dramatic movement layer-to-layer, while the layers closer to the ROF 
will vary greatly and require more frequent redrawing of the ROI.  Once the ROI is completed, 
the image was thresholded and a 3D analysis was performed within the software.  The analysis 
provided tissue volume (TV), bone volume (BV), and a ratio of the two (BV/TV) that represented 
the percentage of total bone.  All data was stored on an 8 terabyte (TB) hard drive (Backup Plus 
Hub, Seagate).  
3.1.2 AIM 1.2: TO DETERMINE THE EFFECTS OF RVX-208 ON ALVEOLAR BONE LOSS IN AN 
ANIMAL PERIODONTITIS MODEL 
Validating the model: A preliminary experiment was conducted in order to confirm that 
a ligature-induced periodontitis model would indeed produce bone loss that could imitate a 
periodontal disease state in male Sprague-Dawley rats.  Briefly, a 3-0 silk ligature was placed 
around the maxillary left second molar.  The accumulation of biofilm and physical irritation 
ultimately resulted in periodontal tissue destruction, which was quantified by our validated 
micro-CT protocol.   
 Male Sprague-Dawley rats (approximately 250-300 g, aged 9-10 weeks) were 
anesthetized with isoflurane.  Rats undergoing suture placement were administered 
buprenorphine for pain management.  3-0 silk sutures were placed into the gingival sulci 
around the left first and second maxillary molars.  Sutures were displaced apically, or replaced 
when necessary, into the gingival sulci weekly to ensure a subgingival position.  The sutures 
were left in place for two weeks to induce experimental periodontitis. A total of 18 rats, with 3 
rats per group, were randomized into the following groups: 
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1) Ligature ligation only 
2) Vehicle treatment (1% DMSO) 
3) 2.5 mM RVX-208 (10% DMSO) 
4) 0.5 mM RVX-208 (2% DMSO) 
5) 0.1 mM RVX-208 (0.4% DMSO) 
6) 0.02 mM RVX-208 (0.08% DMSO) 
The drug was administered to the animal locally by gingival injection, once every other day, 
starting from the day of ligature ligation.  There were two injection sites of 2µL, for a total 
volume of 4µL per animal.  After 2 weeks, the animals were euthanized by CO2 and the maxillae 
were harvested.  The maxillae samples were placed in 10% formalin for 2 days, and then 
transferred to 70% ethanol before being analyzed for bone loss via the aforementioned micro-
CT protocol. 
3.1.3 AIM 1.3: TO PERFORM A HISTOLOGICAL ANALYSIS OF MAXILLAE SAMPLES FROM THE 
ANIMAL PERIODONTITIS MODEL 
 After micro-CT analysis, maxillae samples were decalcified in a 14% EDTA solution that 
was pH balanced to 7.2-7.4 with 5N NaOH.  The samples were placed in the solution with a stir 
bar to ensure constant movement, and placed in a cold room for approximately 14 days.  Once 
soft, the samples were rinsed four times with H2O and placed in 30% EtOH for 30 minutes to 
begin the dehydration process.  The samples were then placed in 50% EtOH for another 30 
minutes.  Finally, the samples were placed in 70% EtOH until ready for sectioning.  With help 
from the CMMC (Cancer Mouse Models Core, Massey Cancer Center, Richmond, VA), the 
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samples were embedded in paraffin blocks and sectioned in the sagittal plane from the buccal 
side so that the roots of M1 and M2 were visible.  The sections were placed on slides and 
stained with Hematoxylin and Eosin (H&E).  The H&E stain helped visualize tissue morphology 
and allowed for qualitative analysis of the samples.  
 
3.2 SPECIFIC AIM 2: TO DETERMINE THE MOLECULAR MECHNISMS OF RVX-208 ON 
PREVENTING ALVEOLAR BONE LOSS IN PERIODONTAL DISEASE 
 Studies in Aim 2 seek to examine the genetic and epigenetic effects of RVX-208 on both 
murine and human cell lines, specifically in regards to its abilities to suppress inflammatory 
cytokine production and inhibit osteoclast differentiation.  The reduction of the host immune 
response and inhibition of bone loss could ultimately halt periodontal disease progression.  The 
hypothesis is that RVX-208 would suppress the inflammatory response induced by the keystone 
pathogen of periodontal disease, while also inhibiting osteoclast differentiation by suppressing 
osteoclast-associated gene expression. 
3.2.1 AIM 2.1: TO DETERMINE THE EXTENT TO WHICH RVX-208 INHIBITS OSTEOCLAST GENE 
EXPRESSION 
 RAW264.7 cells were seeded in a 48-well plate with low glucose DMEM + 10% heat-
inactivated fetal bovine serum (HI-FBS) + 1% penicillin and streptomycin (PS) at a density of 
5000 cells/well.  Cells were incubated at 37° C for 24 hours until confluent and adherent.  On 
Day 1, the medium was changed, and cells were treated with 100 ng/mL RANKL and either 0, 5, 
or 10 µM RVX-208.  The cells were placed back in the incubator and left undisturbed.  On Day 3, 
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the medium was changed and the cells were retreated.  Cell supernatant was harvested on Day 
5 and centrifuged (4° C, 10 minutes, 16.0 RCF).  350 µL of Lysis Buffer RLY (Bioline) was added to 
each well after the supernatant was collected.  RNA was collected and purified per the ISOLATE 
II RNA Mini Kit (Bioline).  The concentrations of the RNA were obtained using a NanoDrop One 
(Thermo Scientific).  cDNA was then generated from the sample RNA using SensiFAST cDNA 
Synthesis Kit (Bioline).  Finally, Real Time-PCR was conducted on the cDNA samples using 
SensiFAST Probe Lo-ROX Kit (Bioline).  The 8 primers used during RT-PCR were those thought to 
be associated with osteoclast differentiation and included nfatc-1, c-fos, Oscar, ctsk, trap, clcn7, 
ostm, and traf6. QuantStudio 3 (AppliedBiosystems) was the machine utilized, and the data was 
analyzed in an Excel Spreadsheet.  
3.2.2 AIM 2.2: TO DETERMINE THE EXTENT TO WHICH RVX-208 SUPPRESSES THE 
INFLAMMATORY CYTOKINE PRODUCTION WHEN CHALLENGED BY P. gingivalis BACTERIA 
 RAW264.7 cells were seeded in a 48-well plate with low glucose DMEM + 10% HI-FBS + 
1% PS at a density of 50,000 cells/well.  Cells were incubated at 37° C for 24 hours until 
confluent and adherent. On Day 1, the medium was changed and the cells were treated with 
either 0, 5, 10, or 30 µM RVX-208 and challenged P. gingivalis bacteria at an MOI of 500.  The 
supernatant was harvested at 12 hours and centrifuged (4° C, 10 minutes, 16.0 RCF).  Murine IL-
6 ELISA was performed on the supernatant, and the results were normalized to DNA content.   
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3.2.3 AIM 2.3: TO DETERMINE THROUGH WHICH BROMODOMAIN PROTEIN OF THE BET-
PROTEIN FAMILY THE EFFECTS OF RVX-208 ARE MEDIATED 
 We first ensured that the effects of RVX-208 were not specific to only murine cells and 
that they could elicit a response in human cells as well. THP-1 cells were seeded in a 48-well 
plate with 1640 RPMI + 10% FBS + 1% PS at a density of 100,000 cells/well.  PMA (10 ng/mL) 
was added to ensure cell adherence.  Cells were incubated at 37° C for 24 hours until confluent 
and adherent.  On Day 1, the medium was changed and the cells were treated with either 0, 10, 
30, or 90 µM RVX-208 and challenged with E. coli-LPS (500 ng/mL) in one trial and with heat-
killed P. gingivalis bacteria (MOI 500) in another.  The supernatant was harvested at 12 hours 
and centrifuged (4° C, 10 minutes, 16.0 RCF).  Human IL-6 ELISA was performed on the 
supernatant, and the results were normalized to DNA content. 
 Once THP-1 cells were determined to be viable candidates for investigating the effects 
of RVX-208, a knockdown cell line for BRD2 was created.  Initially, 2 separate gRNAs were 
created using the known sequence of BRD2, and one additional gRNA was purchased 
(GenScript).  The forward and reverse gRNA oligonucleotides were then annealed by adding 1 
µL of the forward and 1 µL of the reverse oligonucleotide along with 8 µL of dH2O and 
thermocycled (GenAmp PCR System 9700, Applied Biosystems) at 37° C for 30 minutes, 95° C 
for 5 minutes, and then ramped down to room temperature (25° C) at 5° C/minute. To digest 
the vector plasmid, 2 µL Tango Buffer, 1 µL BsmBI enzyme (Thermo Fisher), 1 µg lentiCRISPRv2 
(Addgene) and dH2O were combined for a total volume of 20 µL and placed in a warm water 
bath (37° C) for 1 hour.  Finally, the annealed oligonucleotides and digested vector were ligated 
by adding 2.5 µL T4 DNA Ligase Buffer, 1 µL of the annealed oligonucleotides, and 1.5 µL T4 
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DNA Ligase directly to the digested vector solution.  For the control, 1 µL of dH2O was 
substituted for the oligonucleotides.  The resulting solution was placed into a warm water bath 
for 1 hour.   
 To transform the plasmids into Stbl3 bacteria, a vial of chemical competent Stbl3 cells 
was thawed on ice and 5 µL of plasmid DNA was carefully pipetted onto the top layer of 
bacteria and then incubated on ice for 30 minutes.  The vials were then heat-shocked in a hot 
water bath (42° C) for 45 seconds, and then placed back on ice for 2 minutes.  250 µL of pre-
warmed (37° C) S.O.C. Medium (New England Bio Labs) was added to each vial and the vials 
were shaken horizontally at 37° C for 1 hour at 225 in a shaking incubator.  The vials were then 
removed from the incubator and 100 µL of solution from each transformation were spread on 
pre-warmed agar plates selective for ampicillin resistance.  The agar plates were then incubated 
overnight at 37° C. 
 To isolate the plasmid DNA from the bacteria, 2 colonies from each plate were selected 
and inoculated in 4 mL of LB Broth (Fisher Scientific) and 4 µl ampicillin overnight.  The resulting 
solution was then centrifuged (12,000 RCF, 4° C, 15 minutes) and the plasmid DNA was 
extracted and purified following the protocol for the PureLink Quick Plasmid DNA Miniprep Kit 
(Invitrogen).  The resulting DNA was then sequenced (DNA Core, Nucleic Acids Research 
Facilities, Virginia Commonwealth University) and compared to the initial gRNA sequences to 
ensure successful transformation.  The verified sequences were then transformed into Stbl3 
bacteria, re-plated, and then inoculated overnight to amplify the desired DNA.  The 4 mL of 
inoculated bacteria was then placed into 100 mL of LB Broth and allowed to inoculate 
overnight.   
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 The 100 mL of inoculated verified bacteria was then centrifuged (12,000 RCF, 4° C, 15 
minutes), and the amplified plasmid DNA was extracted and purified following the protocol for 
the HiSpeed Plasmid Midi Kit (Qiagen).  The resulting DNA was then sequenced and again 
compared to the initial gRNA sequences to ensure successful transformation.   
 To infect THP-1 cells with the verified plasmid DNA, HEK 293FT cells were first seeded in 
a 10-cm dish at a density of 5 x 106 cells in complete DMEM medium.  On Day 1, old medium 
was removed and the 293FT cells were transfected with the target plasmid.  1 mL opti-MEM 
(Gibco Laboratories), 12 µg target plasmid, 6 µg pMD2G (Addgene), and 6 µg psPAX (Addgene) 
were combined in a 1.5 mL Eppendorf tube, while 1 mL opti-MEM and 60 µL Lipofectamine 
2000 were combined in a separate tube.  Both tubes sat at room temperature for 20 minutes 
before they were combined and added dropwise to the 10-cm dish with fresh medium.  The 
293FT cells were incubated at 37 C undisturbed for 48 hours.  On Day 2, THP-1 cells were 
seeded at 5 x 105 cells/well in a 6-well plate with 1640 RPMI + 10% FBS + 1% PS to ensure ~50% 
confluency by Day 3.  On Day 3, the THP-1 cells were infected with the viral supernatant.  The 
supernatant was collected from the 293FT cells and centrifuged (1,800 RCF, 4° C, 15 minutes).  
The centrifuged supernatant was filtered through a 0.45 µm syringe filter into a 15 mL tube.  
The supernatant was then added to the wells at a ratio of 1.1 µL/1000 cells, along with 
polybrene (8 µg/mL) and mixed by pipetting up and down.  The cells were then mixed via 
pipette every 2-3 hours, and allowed to culture overnight in a 37° C incubator.  After culturing 
for 24 hours, the viral supernatant was removed and replaced with fresh medium.  After 48 
hours, the medium was replaced with medium selective for puromycin resistance (1 µg/mL).  
The puromycin-selective medium was changed every 3-5 days. 
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 To confirm BRD2 knockdown in the THP-1 cell line, a Western Blot was performed.  First, 
1 mL of Pierce RIPA Buffer (Thermo Scientific) and 10 µL of Halt Protease Inhibitor Cocktail 
(Thermo Scientific) were combined on ice.  The THP-1 cells were centrifuged (180 RCF, 4° C, 7 
minutes), the old medium was removed, and the lysis buffer was added to the pellet in an 
approximate ratio of 1:3.  The lysis solution was then sonicated at 30% amplitude in 3 second 
pulses 8-10 times, and centrigued (13,000 RCF, 4° C, 10 minutes).  The resulting protein was 
assayed using a macro BCA protein assay (Pierce) to determine protein concentration.   
 For the Western Blot, a Mini-PROTEAN TGX Gel (BioRad) was loaded with 10 µg of the 
isolated protein and run at 120 mV for 45 minutes.  The gel was then transferred to an Immun-
Blot PVDF Membrane (BioRad) at 300 mA for 90 minutes on ice.  The resulting membrane was 
then blocked by placing in 5% milk and rocked for 1 hour.  To attach the primary antibody, the 
membrane was placed in a plastic sleeve and filled with 10 mL 5% milk and 2 µL Rabbit Anti-
BRD2 antibody (Bethyl Laboratories) (1:5,000 dilution).  The sleeve was then sealed and placed 
on a rocking table in a cold room (4° C) overnight.  The membrane was removed and washed in 
0.1% PBST 3 times for 5 minutes each.  To attach the secondary antibody, the membrane was 
placed in a plastic sleeve and filled with 10 mL 5% milk and 1 µL Goat Anti-Rabbit IgG (SBI 
System Biosciences) (1:10,000 dilution).  The sleeve was sealed and rocked at room 
temperature for 2 hours.  The membrane was then washed in 0.1% PBST as above, and allowed 
to soak in 2 mL SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific).  The 
prepared membrane was then imaged using blue BioExcell 5x7 Autoradiographic Film (World 
Wide Medical Products Inc.).  All imaging was performed in a dark room.   
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3.3 STATISTICAL ANALYSIS 
 ELISA and bone volume data were calculated in Excel spreadsheet.  The results were 
input into GraphPad Prism 7 software to create bar graphs and histograms.  Statistical analysis 
was done in this software using a parametric one way ANOVA (p<0.05) and Tukey’s multiple 
comparisons test.  P-values were indicated using asterisks as follows: * (p,0.05), ** (p<0.01), 
*** (p<0.001), **** (p<0.0001). 
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CHAPTER 4: RESULTS 
 
 
4.1 SPECIFIC AIM 1: TO FURTHER VALIDATE THE IN VIVO EFFECTS OF RVX-208 ON A 
LIGATURE-INDUCED PERIODONTITIS MODEL IN RATS 
 After establishing and validating a reliable and repeatable micro-CT protocol, samples 
from the ligature-induced periodontitis model were analyzed using the micro-CT protocol and 
other statistical regressions.  
4.1.1 AIM 1.1:  TO VALIDATE THE MICRO-CT PROTOCOL FOR ANALYZING LINEAR AND 
VOLUMETRIC DATA FROM THE PERIODONTITIS MODEL IN RATS 
 To ensure accurate quantitative measurements of samples from the ligature-induced 
periodontitis animal model, the protocol we created to measure the bone volume of the 
samples needed to be stream lined and verified by multiple trials.  Previously, our group 
performed a ligature-induced periodontitis model and ligatures were ligated around the left 
maxillary M2 of three rats.  The alveolar bone loss was compared to the right maxillary molars 
of the same animals, as well as the left maxillary molars of three rats without ligature ligation.  
Statistical analyses (Fig. 6) of volumetric analysis data showed that the right side of the 
experimental animal was highly similar to control group.  Additionally, there was no significant 
difference between different analyses of the same sample using the volumetric protocol when 
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repeated by two separate researchers.  These findings suggest that our protocol is repeatable 
and reliable. 
 
Figure 6: Bone volume of maxillae samples from the experimental model – the left side of the maxilla that 
received the ligature had significantly less bone volume than the right side of the maxilla of the same animal.  
Two separate researchers NC (Nicholas Clayton) and MS (Mingxu Sun) verified the measurements of the left side 
no treatment group following the developed protocol and a similar trend was observed in their analyses.    
 
4.1.2 AIM 1.2: TO DETERMINE THE EFFECTS OF RVX-208 ON ALVEOLAR BONE LOSS IN AN 
ANIMAL PERIODONTITIS MODEL 
 To begin in vivo testing, we first had to verify that the experimental periodontitis model 
could reliably induce bone loss similar to what you would expect to find in patients suffering from 
periodontal disease.  In our first experimental trial, ligature placement induced significant 
alveolar bone loss in the animals both in linear (Fig. 8) (ligature: p<0.001) and volumetric 
measurements (Fig. 10) (ligature to control: p<0.0001, ligature to R.side: p<0.001).  Once the 
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experimental model was verified, the model was replicated and rats were injected with varying 
concentrations of RVX-208 (0-2.5 mM) for two weeks.  The left maxillae were harvested, and the 
samples were analyzed for linear (Fig. 7) and volumetric (Fig. 9) bone loss using the validated 
MicroCT protocol.  Linear bone loss was significantly reduced both between M1 and M2 as well 
as between M2 and M3 for medium to high doses (0.5-2.5 mM, p<0.01) (Fig. 11).  A dose-
dependent response was observed in volumetric measurements, as BV/TV was positively 
correlated with RVX-208 dosages, although it did not reach statistical significance due to the small 
sample size (n=3) (Fig. 12).  The decrease in linear and volumetric bone loss indicates that RVX-
208 can ameliorate bone loss in patients suffering from periodontal disease. 
 
Figure 7: Linear measurement of alveolar bone crest (ABC) and cementoenamel junction (CEJ) – micro-CT scans 
were analyzed in the sagittal plane to find the midpoint (blue dot) between the CEJs (red arrows) of M1 and M2.  
The distance measured was from the midpoint to the ABC, denoted by the white arrow.  
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Figure 8: Linear bone measurement of ligature model validation experiment – Measurements were made 
between the cementoenamal junction and alveolar bone crest.  The linear measurements of the ligature 
samples were significantly larger than both the right side of the same animal and the control group, denoting 
greater bone loss (***: p<0.001).  
 
Figure 9: Volumetric analysis – micro-CT scans were isolated for a region of interest in the transversal plane with 
the maxillary second molar M2 as the center, the most mesial root of M3 as the left boundary, and the most 
distal root of M1 as the right boundary.  1.) A volume of interest (VOI, shown in red) was established beginning 
80 layers or 1 mm below the roof of furcation, and included non-tooth tissue encompassed by the midpoints of 
each root. 2-3.) The VOI was redrawn every 4-5 layers to account for root migration 4.) The roof of furcation 
represents the top-most boundary of the VOI.   
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Figure 10: Bone volume of maxillae samples from the ligature-induced experimental periodontitis model – the 
ligature group showed a significant loss of bone volume when compared to the right side of the same animal 
and the control group (***: p<0.001, ****: p<0.0001).  There was no difference between the right side of the 
experimental animal and the control group. 
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Figure 11: Linear measurements of samples from the ligature-induced periodontitis model – Measurements 
were made between the cementoenamel junction and the alveolar bone crest.  Mean linear bone loss was 
calculated by averaging the linear measurements of M1-M2 and M2-M3.  Total linear bone loss was calculated 
by adding the total measurements of M1-M2 and M2-M3.  There was significantly less bone loss when RVX-208 
was administered at medium to high doses (0.1 mM-2.5 mM: p<0.01). 
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Figure 12: Bone volume measurements of samples from the ligature-induced periodontitis model.  The slight 
upward trend indicates a positive correlation between an increased dose of RVX-208 and an increase in retained 
bone volume.  
4.1.3 AIM 1.3: TO PERFORM A HISTOLOGICAL ANALYSIS OF MAXILLAE SAMPLES FROM THE 
ANIMAL PERIODONTITIS MODEL 
 Aside from quantitative analyses of the ligature-induced periodontitis model, 
histological analysis can provide insight as to what effects RVX-208 may have on a tissue 
morphology.  Harvested maxillae samples were decalcified in EDTA, embedded in paraffin, and 
sectioned serially.  The sections were then stained with H&E to highlight the morphology of the 
periodontal tissue between M1 and M2.  As shown in Fig. 13, the distance between the alveolar 
bone crest and cementoenamel junction is dramatically decreased in the higher doses of RVX-
208, while also appearing to have a slight effect on decreasing bone volume.   
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Figure 13: H&E stained histology sections from a ligature-induced periodontitis model.  The distance between 
the CEJ and the ABC is in italics.  The ABC is marked by the black arrow.  Qualitatively, the most profound 
difference can be seen between the DMSO group and the higher dosages of RVX-208 (0.5 mM and 2.5 mM).  
 
4.2 SPECIFIC AIM 2: TO DETERMINE THE MOLECULAR MECHNISMS OF RVX-208 ON 
PREVENTING ALVEOLAR BONE LOSS IN PERIODONTAL DISEASE 
 Cell culture assays were performed to determine the mechanisms through which RVX-
208 suppresses osteoclast differentiation, its ability to suppress the inflammatory response 
initiated by whole pathogens, and to determine if its effects were species-specific.  Finally, a 
knock down human cell line was generated and confirmed for future studies 
4.2.1 AIM 2.1: TO DETERMINE THE EXTENT TO WHICH RVX-208 INHIBITS OSTEOCLAST GENE 
EXPRESSION 
 RAW264.7 cells were induced into osteoclasts by RANKL and then treated with RVX-208 
(0-10 µM).  cDNA was generated from the extracted RNA and RT-PCR was run to determine 
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RVX-208’s ability to suppress the expression of genes associated with osteoclast differentiation.  
When RVX-208 was added, the expression of genes most closely associated with osteoclast 
differentiation were significantly suppressed(trap: p<0.0001, oscar: p<0.0001, ctsk: p<0.0001, 
nfatc-1 5 µM RVX-208: p<0.001, and clcn7 5 µM RVX-208: p<0.01, 10 µM RVX-208: p<0.001) 
(Fig. 14) at both doses (5 and 10 µM). c-fos, traf-6, and ostm-1 were unaffected by RVX-208.  
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Figure 14: RT-PCR of relative gene expression of murine osteoclasts treated with RVX-208 – RAW264.7 cells were 
seeded at a density of 5000 cells/well in a 48-well plate.  Cells were treated with RANKL to induce differentiation 
into osteoclasts and then treated with varying doses of RVX-208.  After 7 days, the cells were harvested and 
cDNA was synthesized from harvested RNA.  RT-PCR was run to examine a panel of genes associated with 
osteoclast differentiation.  The expression of trap, oscar, ctsk, nfatc-1, and clcn7 genes were all significantly 
suppressed (**: p<0.01, ***: p<0.001, ****: p<0.0001) when treated with RVX-208.  The expression of traf-6, c-
fos, and ostm-1 genes were not affected significantly.  
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4.2.2 AIM 2.2: TO DETERMINE THE EXTENT TO WHICH RVX-208 SUPPRESSES THE 
INFLAMMATORY CYTOKINE PRODUCTION WHEN CHALLENGED BY P. GINGIVALIS BACTERIA 
 Recent studies have suggested that the mechanism through which P. gingivalis bacteria 
activates the host immune response does not rely solely on its LPS, as other virulence factors 
may also be involved including bacterial DNA.  Because our preliminary studies utilized LPS 
exclusively, we needed to verify that RVX-208 could also mediate the potentially varied immune 
response activation mechanisms utilized by P. gingivalis bacteria in order to justify clinical 
applicability.  Murine macrophages were challenged with killed P. gingivalis bacteria and 
treated with increasing concentrations of RVX-208 (0, 5, 10, and 30 µM) for 12 hours, and IL-6 
ELISA was performed to determine the effect on inflammatory response through cytokine 
production.  As shown in Fig. 15, RVX-208 was able to significantly reduce the IL-6 production of 
cells challenged with P. gingivalis bacteria (*: p<0.5, ****: p<0.0001).  These findings are in 
concordance with our findings for the effects of RVX-208 on P. gingivalis-LPS, and suggest RVX-
208 can suppress the inflammatory response regardless of the initiating factor.  
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Figure 15: ELISA IL-6 Results – RAW264.7 cells were seeded at a density of 50,000 cells/well in a 48-well plate.  
The cells were challenged with P. gingivalis bacteria at an MOI of 500 and then treated with varying 
concentrations of RVX-208 for 12 hours.  The assay shows a significant suppression of cytokine expression (****: 
p<0.0001).  N.D. = non-detectable: the IL-6 kit utilized was not able to detect the lowest concentrations of IL-6 
produced in our trials. 
4.2.3 AIM 2.3: TO DETERMINE THROUGH WHICH BROMODOMAIN PROTEIN OF THE BET-
PROTEIN FAMILY THE EFFECTS OF RVX-208 ARE MEDIATED 
 Before investigating the roles of specific bromodomain proteins, we needed to verify 
that the effects of RVX-208 were not species specific.  Human clinical trials are essential to the 
development of RVX-208 as a treatment option for periodontal disease, thus, the effects of 
RVX-208 need to be established in a human cell line.  To test this, THP-1 cells were challenged 
with P. gingivalis bacteria and then treated with RVX-208 for 12 hours, and IL-6 ELISA was 
performed to determine the effect on inflammatory response through cytokine production.  As 
a positive control, THP-1 cells were challenged with E. coli-LPS and treated with RVX-208 as 
before.  As shown in Fig. 16, not only were E. coli-LPS and P. gingivalis bacteria able to stimulate 
the immune response of THP-1 cells, but RVX-208 was able to combat that immune response by 
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significantly suppressing the production of inflammatory cytokines (****: p<0.0001).  These 
findings confirm that the effects of RVX-208 are not species specific in regards to eliciting a 
response in both human and mouse cell lines, and that THP-1 cells are a viable cell line to 
examine the effects of specific bromodomain proteins.   
 
Figure 16: ELISA IL-6 Results – THP-1 cells were seeded at a density of 100,000 cells/well in a 48-well plate.  The 
cells were challenged with E. coli-LPS (left) or P. gingivalis bacteria (right) and then treated with increasing 
concentrations of RVX-208.  Both trials demonstrate a significant suppression of IL-6 production when treated 
with RVX-208 (****: p<0.0001). N.D. = non-detectable: the IL-6 kit utilized was not able to detect the lowest 
concentrations of IL-6 produced in our trials. 
 Once a viable human cell line was established, the first step in isolating the effects of 
each bromodomain protein is to generate a cell line in which the protein of interest is knocked 
down via a CRISPR/Cas9 system.  Since it has been shown that RVX-208 has a higher binding 
affinity to the BD2 domain of BRD2 when compared to other BRD proteins, we asked the 
question if the effects of RVX-208 on periodontal inflammation was directly associated with 
BRD2.  In order to investigate this, we designed two separate guide RNAs representing different 
target regions of the genomic indels of BRD2, while a third guide RNA was purchased.  Fig. 17 
shows the sequence of BRD2 and where the gRNA were designed to produce their respective 
indels.  Those gRNAs were ligated into a plasmid vector, and that plasmid was transfected into 
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chemically-competent Stbl3 bacteria to amplify the plasmid DNA.  After a miniprep, the isolated 
plasmid DNA was sent to be sequenced to confirm the presence of our gRNA.  The validated 
sequences were re-transfected into the bacteria, and a midiprep was performed to further 
amplify the plasmid DNA.  The verified plasmid DNA was then transduced into HEK293FT cells, 
which produced a viral supernatant containing our vectors.  The viral supernatant was used to 
infect THP-1 cells, which were then selected with puromycin.  Those cells were grown in 
medium until stable, and a Western Blot was performed to examine the extent of BRD2 
knockdown.  Western Blot results (Fig. 18) demonstrate a significant knockdown effect 
observed in all three gRNAs, the most dramatic of which can be seen in gRNA2-2.  These 
findings demonstrate a successful knockdown of BRD2 protein function, and can be used in 
later experiments to investigate the role of BRD2 in mediating the anti-inflammatory effects of 
RVX-208 in periodontal disease.   
Figure 17: Sequence layout of BRD2 and indel locations of designed guide RNAs (gRNA) – each gRNA was 
designed directly preceding a PAM sequence to ensure proper CRISPR function.  gRNA 1 was purchased, while 
gRNAs 2 and 3 were designed using the described genomic sequence of BRD2.   
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Figure 18: Western blot panel of BRD2 knockdown in THP-1 cells – 10 µg of cell lysate was loaded onto a gel and 
run to examine the efficacy of plasmid transfection into THP-1 cells.  The weaker signals of the constructed 
gRNAs compared to the control indicates some degree of knockdown in our THP-1 cell lines.  The relative 
normalized ratio was calculated by normalizing the experimental bands to β-actin, which was then normalized 
to the control group  Guide RNA (gRNA) sequence locations are detailed in Fig. 17.  
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CHAPTER 5: DISCUSSION 
 
 
 The findings presented in this work showcase the ability of the selective bromodomain 
and extraterminal domain (BET) protein inhibitor, RVX-208, to ameliorate bone loss in a 
ligature-induced experimental periodontitis model in rodents, while also detailing optimized 
methods to quantify the results of the model. RVX-208 was able to significantly suppress the 
expression of genes directly associated with osteoclast differentiation and maturation in 
murine RAW264.7 cells, and was shown to dampen the inflammatory response initiated by 
both E. coli-LPS and P. gingivalis bacteria in human THP-1 cells.  Finally, this study also details 
the successful generation of a BRD2-knockdown THP-1 cell line that can be utilized to 
investigate the roles that the specific bromodomain protein BRD2 plays in the mediation of the 
effects of RVX-208. 
 In Aim 1, we began by validating the micro-CT protocol we had devised given the 
objectives of our study.  We performed a small scale animal study in which we placed ligatures 
on one group of rodents, and left the others as a control.  After analyses by two different 
researchers (MS and NC), we found that not only did our ligature model significantly induce 
bone loss, but that our micro-CT protocol for quantifying the data was reliable and reproducible 
based on the high consistency between separate analyses.  Once the model was established 
and verified, our in vivo periodontitis experiment demonstrated RVX-208’s ability to 
significantly reduce the bone loss seen in our control groups.  Linear measurements showed 
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that the amount of bone loss decreased as the dose of RVX-208 increased (up to 2.5 mM), while 
the volumetric measurements suggested a similar relationship without being statistically 
significant.  It is our belief that had the sample size been greater than 3 rodents per group, the 
volumetric data would have shown a significant correlation between a decrease in bone loss 
and an increase in the dosage of RVX-208, based on the obvious trend in Fig. 5.  Our study 
provided valuable preliminary data enabling us to perform powerful analysis for our future 
experiments.  Interestingly, we saw more pronounced bone loss on average in the periodontal 
space between M1 and M2 when compared with the area between M2 and M3.  To further 
verify our findings, histological sections were created from the maxillae samples harvested from 
the periodontitis model.  Qualitatively, the slides stained with H&E demonstrated a clear 
morphological difference in the periodontal tissue between samples that had been treated with 
higher doses of RVX-208 and samples that had not been treated with RVX-208.  In the future, 
those histological slides can be used to quantify the effects of RVX-208 in vivo through the 
analysis of inflammatory cell infiltrate in conjunction with a TRAP stain to examine osteoclast 
activity. 
 In Aim 2, we explored some of the mechanisms through which RVX-208 is able to 
mediate the effects seen in Aim 1.  We showed that RVX-208 is able to suppress or halt bone 
loss altogether through the suppression of genes closely associated with the differentiation and 
maturation of osteoclasts.  The genes trap, oscar, ctsk, nfatc-1, and clcn7 were all shown 
suppressed to a highly significant degree.  The suppression of oscar, a gene that codes for the 
osteoclast-associated Ig-like receptor, severely impedes an osteoclast-precursor’s ability to 
differentiate into an osteoclast, ultimately reducing the overall presence of mature osteoclasts.  
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Additionally, the suppression of ctsk, which codes for cathepsin K, a protease involved in bone 
remodeling and resorption, and clcn7, which codes for an important H+/Cl- exchange 
transporter, all retard the cell’s ability to mature into a fully functional osteoclast, decreasing 
the effectiveness of the few precursors that are able to differentiate.  Finally, RVX-208 had no 
effect on the expression of traf6, the gene that codes for TNF-associated receptors as well as 
some Toll-like receptors, demonstrating that RVX-208 does not interfere with the upstream 
cascade of the NF-κβ pathway, but rather suppresses the inflammatory cytokine gene 
expression directly through its inhibition of BRD proteins.   
 Recent evidence has suggested that whole pathogens may induce immune responses 
varying from those induced by lipopolysaccharides (), so we wanted to ensure that the effects 
of RVX-208 were universal, regardless of the initiating mechanism.  We demonstrated that RVX-
208 could significantly reduce the inflammatory response initiated by P. gingivalis bacteria, 
which was in agreement with our previous findings on the suppressive effects of RVX-208 on 
cells challenged with P. gingivalis-LPS.  This has direct implications in the clinical applicability of 
RVX-208 as a therapeutic drug for periodontal disease, as we’ve shown that RVX-208 
consistently suppresses the inflammatory cascade regardless of the mediator, and is especially 
effective against the clinical keystone pathogen of periodontal disease, P. gingivalis.   
 We also demonstrated that the effects of RVX-208 are not species specific.  THP-1 cells, 
a human monocytic cell line derived from an acute monocytic leukemia patient, are commonly 
utilized in studies investigating oral pathogenesis.  We demonstrated that RVX-208 could 
suppress the inflammatory response initiated by both E. coli-LPS and P. gingivalis bacteria in 
THP-1 cells.  By establishing a viable human cell line that responds positively to the anti-
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inflammatory effects of RVX-208, further studies on RVX-208 can be directly applied to humans.  
Additionally, this allowed us to begin the generation of a knockdown cell line to examine the 
effects of RVX-208 on specific members of the BET protein family.  Of the three BET proteins, 
RVX-208 has shown to be highly selective towards BD2 of BRD2 ().  Cheng, et al. examined the 
mechanics of a novel orally active BETi with selectivity for BD2, RVX-297, and found that RVX-
297 exhibited a higher inhibitory activity to BD2 as compared to RVX-208.  Because RVX-297 has 
been shown to reduce inflammatory cytokines, reduce inflammatory gene expression, counter 
the pathology of inflammatory diseases like polyarthritis, and even prevent disease 
development in models of human multiple sclerosis in rats (77), the elucidation of the 
molecular mechanisms responsible for the selectivity of selective BET inhibitors, like RVX-208 
and RVX-297, is a key step in advancing BET-inhibitor design for anti-inflammatory and 
autoimmune therapeutics.  As such, we designed a CRISPR/Cas9 system to knock down the 
BRD2 protein in THP-1 cells, and verified the knock down via Western Blot.  The Western Blot 
confirmed a successful knock down of BRD2 for at least one of our designed gRNAs.  This cell 
line can be used in the future to investigate whether RVX-208 can still suppress the 
inflammatory response without the presence of BRD2.   
 While RVX-208 is the first and only BET inhibitor to reach Phase III clinical trials, a few 
lingering issues regarding the widespread use of BET inhibitors in a clinical setting still remain.  
Studies have indicated that BET protein BDs function cooperatively (35).  How BD1 is impacted, 
either directly or indirectly, through BD2-selective inhibition requires further investigation.  
Additionally, because BET inhibitors simultaneously downregulate multiple inflammatory 
processes in contrast to targeting single entities in inflammatory pathways per traditional 
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treatment methods, adverse effects on systemic suppression of inflammatory cascades could 
be potentially detrimental, highlighting the need for tissue-specific targeting.  One problem that 
still persists is the method through which RVX-208 can be applied orally.  Due to its short half-
life, a method needs to be developed in which the lifespan of the drug is sustained while also 
delivering an efficacious dose.  Additionally, suppression of the host immune response by RVX-
208 raises concerns about overall immune susceptibility.  While methods for measuring the 
systemic immunity remain inexact, one method for determining the ability of RVX-208 to impair 
the body’s ability to fight off infection could be through utilization of a salivary swab and then 
subsequent next-gen DNA sequencing for bacterial composition done before and after 
treatment with RVX-208.  If RVX-208 had a negative effect on the body’s immune system, then 
that pathogen oral biofilm would theoretically be different than from that of a healthy immune 
system. While more studies are still needed to evaluate the efficacy of RVX-208 as a treatment 
for periodontitis, past results on selective BET inhibitors in conjunction with the findings 
detailed in this study for its direct application are highly promising. 
 In future studies, the effects of RVX-208 should be examined in vivo in larger animals, 
and with a larger sample size.  The significance of our volumetric data was lacking due to our 
small sample size, yet a dose dependent effect was noticed.  Using the BRD2 knock down cell 
line generated in this study, the interplay between BRD2 and RVX-208 should be elucidated.  
Additionally, knock down cell lines should be generated for the remaining two BRD proteins, 
BRD3 and BRD4.  Finally, a mode of application needs to be investigated, as subgingival 
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injections twice a day are not feasible for human patients. 
 
Figure 19: Summary of the effects of RVX-208 in the host immune response initiated by a keystone pathogen of 
Periodontitis.  By suppressing the genes associated with osteoclastogenesis and by preventing the recruitment 
of transcription factors, RVX-208 can suppress the inflammatory response and inhibit bone resorption.  
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CHAPTER 6: CONCLUSION 
 
 
 Periodontal disease therapies currently focus on mechanical debridement, which does 
little to combat the over-exuberant host immune response that is ultimately responsible for 
periodontal tissue degradation.  With these therapies, bacterial reinfection is common, and 
antibiotic resistance is a growing concern.  The development of host modulation therapies are 
an unmet need in the treatment of periodontal disease.  One such host response modulator, 
BET-inhibitor RVX-208, may provide an alternative method through which to control the host 
immune response, suppress inflammation, and decrease the bone loss that is characteristic of 
periodontal disease.  
 Our study sought to observe the effects of RVX-208 on reducing inflammation and 
ameliorating bone loss in a ligature-induced model of periodontitis.  As the exact mechanism of 
RVX-208 is relatively unknown, we also sought to examine the mechanisms through which RVX-
208 mediates its effects.  RVX-208 significantly decreased bone loss in a ligature induced 
periodontitis model.  Qualitatively, the linear distance between the ABC and the CEJ was 
reduced as the dosage of RVX-208 increased.  We showed that RVX-208 can stifle bone loss 
through suppression of genes closely associated with the differentiation and maturation of 
osteoclasts such as trap, oscar, ctsk, and clcn7.  Finally, we demonstrated that the effects of 
RVX-208 are not species specific, and can successfully combat the host immune responses 
initiated by both P. gingivalis-LPS and whole pathogen bacteria in humans.  Larger sample sizes 
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should be utilized in future in vivo studies, while also testing alternative drug delivery 
techniques.  Overall, we can conclude that treatment with RVX-208 can ameliorate bone loss in 
a ligature-induced periodontitis model through directly suppressing the expression of 
osteoclast genes, while also suppressing the inflammatory response initiated by multiple 
pathogens.  Thus, RVX-208 remains at the forefront of promising host-modulation therapies for 
combating periodontal disease.   
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